Optimizing the Use of Novel Therapies for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) — September 28, 2026, Fort Wayne, IN

A CME/MOC-Accredited Interactive Grand Rounds Series

Date
Monday, September 28, 2026

Program Schedule — Eastern Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 7:30 PM — Educational Program

Location
Biaggi’s Ristorante Italiano
4010 W Jefferson Blvd
Fort Wayne, IN 46804

Meeting Room
Banquet Room

Faculty

Matthew Matasar

Rutgers Cancer Institute, New Brunswick, New Jersey

Chief, Division of Blood Disorders

Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

Hematologist/Oncologist, Professor

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large b-cell lymphoma (DLBCL).

I am a:(Required)

Clinician / healthcare professional

Other / industry professional

Name(Required)

First Last

Email(Required)

Address(Required)

City State / Province / Region Country

Degree(Required)

Specialty(Required)

If you are a clinician, which of the following best describes your practice setting?(Required)

National Provider Identifier (NPI) Number

These activities are supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pfizer Inc.